Oda M, Watanabe S, Tsukayama S, Tomita Y, Ohta Y, Murakami S, Watanabe Y
Department of Surgery, Kanazawa University, School of Medicine, Japan.
Kyobu Geka. 1998 Oct;51(11):902-6.
The purpose of this study was to evaluate the results of surgical treatment of T3N0-2M0 non-small cell lung cancer according to involved organ and nodal status. Between 1973 and July 1997, 157 patients with T3 non-small cell lung cancer were surgically treated in our department. Five-year survival was 23% for all cases, 35% for patients with curative resection, and 0% for patients with non-curative resection (p < 0.001). Five-year survival rate of patients with T3N0, T3N1, and T3N2 was 37%, 39%, and 3%, respectively (T3N0 vs T3N2, T3N1 vs T3N2, p < 0.01). According to the depth of chest wall involvement of T3N0 tumor, 5-year survival rate was 50% in the patients with the involvement of parietal pleura, 39% in the patients with the involvement of intercostal muscle, and 15% in the patients with the involvement of rib or more (parietal pleura vs rib or more, p < 0.05). In T3N0 patients with the involvement of only parietal pleura, the 5-year survival rate of parietal pleurectomy and en bloc chest wall resection was 43% and 46%, respectively (N.S.). Five-year survival rate of T3N1 patients with invasion in main stem bronchus was 46% and 3 of 5 patients of T3N0-1 tumor with pericardial invasion survived more than 5 years. From these results, T3N0 tumor involving chest wall without rib invasion, and T3N0-1 tumor involving main bronchus and pericardium are expected good survival. However, the prognosis of the patients with coexistent N2 disease or with incomplete resection remains poor in regardless with the type of involved organ. To correctly evaluate the surgical results of other types of T3 tumor, it is required to collect more cases or to perform multicenteric study.
本研究的目的是根据受累器官和淋巴结状态评估T3N0 - 2M0非小细胞肺癌的外科治疗结果。1973年至1997年7月期间,我科对157例T3非小细胞肺癌患者进行了外科治疗。所有病例的5年生存率为23%,根治性切除患者为35%,非根治性切除患者为0%(p<0.001)。T3N0、T3N1和T3N2患者的5年生存率分别为37%、39%和3%(T3N0与T3N2、T3N1与T3N2,p<0.01)。根据T3N0肿瘤胸壁受累深度,壁层胸膜受累患者的5年生存率为50%,肋间肌受累患者为39%,肋骨或更深处受累患者为15%(壁层胸膜与肋骨或更深处,p<0.05)。在仅壁层胸膜受累的T3N0患者中,壁层胸膜切除术和整块胸壁切除术的5年生存率分别为43%和46%(无显著差异)。主支气管受侵的T3N1患者的5年生存率为46%,5例T3N0 - 1肿瘤心包受侵患者中有3例存活超过5年。从这些结果来看,未侵犯肋骨的胸壁受累T3N0肿瘤以及侵犯主支气管和心包的T3N0 - 1肿瘤有望获得良好的生存率。然而,无论受累器官类型如何,合并N2疾病或切除不完全的患者预后仍然很差。为了正确评估其他类型T3肿瘤的手术结果,需要收集更多病例或进行多中心研究。